- Home
- AIIO vs FATE Comparison
AIIO vs FATE Comparison
Compare AIIO & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIIO | FATE |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.6M | 124.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | AIIO | FATE |
|---|---|---|
| Price | $0.26 | $1.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.92 |
| AVG Volume (30 Days) | ★ 2.0M | 1.7M |
| Earning Date | 05-27-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,742,000.00 | ★ $7,137,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.66 |
| 52 Week High | $3.48 | $1.94 |
Technical Indicators
Market Signals| Indicator | AIIO | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 29.00 | 63.46 |
| Support Level | $0.23 | $1.02 |
| Resistance Level | $0.29 | $1.22 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 14.25 | 82.86 |
Price Performance
Historical ComparisonAbout AIIO Robo.ai Inc. Class B Ordinary Shares
Robo.ai Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world. Geographically, the company operates in The United States, The United Arab Emirates, Mainland China.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.